Arvinas Inc ASCO Data Conference Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Ellie Merle - Cantor Fitzgerald - Analyst : Hey, guys, thanks so much for taking the question. I was just wondering if you could give us more color on the percent of AR protein that's being degraded in some of these samples that you're looking at, particularly if you could comment on the percent of AR that you saw degraded in the biopsy that you showed on the slides. And then also in the press release, you noted that five patients have CTCs looking at degradations. So, if you could give us any more time like the percent of degradation you saw, if there is any dose-dependent relationship, if there is relationship with percent degradation and response. Just more color on that would be really helpful. Thanks. And then I have a follow-up.

Question: Ellie Merle - Cantor Fitzgerald - Analyst : Got it, thanks, that's helpful. And then just in terms of the time course of the response, as for the two responders like can you kind of maybe give us more color on the cadence or trajectory of the changes in PSA over time? And in particular, if you can disclose I guess what week the patients reached the 50% reduction, just trying to kind of think about that in the context of some of the other patients on -- such as like (inaudible) 00:34:33 seem to have relatively less time on the drugs. Thanks.

Question: Ellie Merle - Cantor Fitzgerald - Analyst : Got it. And then just last one, sorry, on the mutations, I mean you mentioned that going forward, you're going to focus specifically more kind of on these point mutations. I mean is there any conclusion to draw at this point around AR?V7? Is this something that you'll continue to explore or going forward, will you sort of try to enrich for, say, less AR?V7 patients? And also just if you can maybe give us more color on exactly how you're defining the cutoff for AR?V7, that would be helpful. without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Question: Ellie Merle - Cantor Fitzgerald - Analyst : Got it. Thank you so much. I appreciate it.

Question: Terence Flynn - Goldman Sachs - Analyst : Hi, thanks for taking the questions. I guess, first, can you just remind us the frequency at which the PSA data are collected in the study? Is it every four weeks? And then on the biopsy, you -- I think you mentioned it was from the liver, not the prostate. I just wanted to understand kind of the location of the biopsy data. And then the third one I had is just the comment, John, that you made regarding some early evidence of ER degradation with the 471 program. I'm just wondering if that's also biopsy data or is that RECIST tumor response. If you could just give us a little bit more color on that. Thanks. without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Question: Terence Flynn - Goldman Sachs - Analyst : That's right.

Question: Ted Tenthoff - Piper Jaffray - Analyst : Hey, thanks so much, guys, for the update today, lots of interesting information and definitely something (inaudible) 00:40:06 proof of concept. I wanted to really try to understand sort of how you're exploring dose here between sort of the initial liver safety findings would seem to be statin- related, but now, really trying to understand dose at the higher 280 and even above. So, where is that coming and when could we expect the next update on those higher doses? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Question: Ted Tenthoff - Piper Jaffray - Analyst : Great. That's really helpful. (inaudible) on this. Thanks, guys.

Question: Michael Schmidt - Guggenheim Securities - Analyst : Hey, guys, congrats on the data and thanks for taking my questions as well, you know, Maybe just a follow-up on the rosuvastatin potential drug-drug interaction here. This BCRP transporter, are here other drugs that might be potentially affected by this interaction?

Question: Michael Schmidt - Guggenheim Securities - Analyst : Okay, yes, very helpful. Thanks for clarifying that. And then just on the genomic analysis that you mentioned, just curious, maybe on one hand, if you could just comment on sort of the overall frequency of the two potential non-responsive mutations, how quickly did those occur? And in terms of enrichment strategy, potentially in the future, are you thinking about exclusion of those potentially or the other way around, enriching for specific mutations where ARV-110 might be particularly active? Yes.

Question: Michael Schmidt - Guggenheim Securities - Analyst : Okay, very helpful. Thanks and congrats on the presentation again.

Question: Yigal Nochomovitz - Citigroup - Analyst : Hi, guys. Thank you very much for taking the questions and congrats on the -- on the data. I had a few. So, regarding the patient that had the confirmed PSA50 response but didn't have the RECIST response, the one with about a minus -- negative 75% PSA50 response. Was that person RECIST evaluable and didn't have the RECIST response or were they just not RECIST evaluable?

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay, got it. And then I appreciate the comments with respect to the 280 milligram cohort that you haven't had them on therapy long enough to demonstrate a dose response. without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. But I just -- I was just wondering a little bit more as to why you need to backfill the 280 to further explore the dose response when you're already moving forward. With the 420, it would seem that you would be able to do a good job of mapping out the dose response just by looking at 420. Can you just elaborate a little bit more on why you're -- why you're doing the backfilling at 280?

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay, thank you. And then just -- can you just remind us how much higher you could dose in this trial based on your preclinical (inaudible) work?

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay.

Question: Yigal Nochomovitz - Citigroup - Analyst : Got it. And then just two other quick ones. With respect to your next generation compound that's in discovery, the AR variant degrader AR?V7. Is that one expressly for AR?V7 or do you expect that that would have activity against the L702H mutation as well?

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay.

Question: Yigal Nochomovitz - Citigroup - Analyst : Got it. And then just one final one. I was -- I was intrigued by your Slide 5 where you show what looks like the structure of 110, but I wasn't sure. Are you actually disclosing the structure with that slide or is that not accurate?

Question: Yigal Nochomovitz - Citigroup - Analyst : Okay, got it, thank you.

Question: Yigal Nochomovitz - Citigroup - Analyst : Sure.

Question: George Farmer - BMO Capital Markets - Analyst : Hi, good morning and thanks for taking my questions and congratulations on the data. I'd like to ask you about a couple of these patients in the 70 mg cohort who appeared to have been dose-escalated to 140. What was the reason for that and were they evaluable for PSA response?

Question: George Farmer - BMO Capital Markets - Analyst : Okay. And then one thought they find (inaudible) 00:56:35 in the measurements of the patients coming into the trial, I imagine would be pretty wide range. Is there something remarkable about the two responders? Do they have a higher baseline coming in or were they more representative of the overall population? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Question: George Farmer - BMO Capital Markets - Analyst : Okay. And one more if I may. And did you see any impact on bone involvement?

Question: George Farmer - BMO Capital Markets - Analyst : Great, thanks very much.